Pontifax
Pontifax is a venture capital firm that finances pharmaceutical and life sciences companies.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Pontifax Information
Geographic Data
Address: 14 Shenkar Street
City: Herzliya
State: tel aviv district
Zip: -
Country: IL
Financial Info
Stage:
Raised Last:
$0
Raised Total:$460M
Social
Linkedin
Crunchbase
Metrics
8,117,139Website Global Rank
380Website Monthly Traffic
Twitter Followers
Description
Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2020 | Stargazer Pharmaceuticals | Series A | 0 |
| 8/2017 | Eloxx | Series C | 0 |
| 11/2017 | Keros Therapeutics | Series A | 11M |
| 1/2016 | Ocon Healthcare | Venture Round | 0 |
| 11/2017 | Coave Therapeutics | Series B | 22M |
| 1/2016 | V-Wave | Series B | 0 |
| 7/2020 | ProQR Therapeutics | Post-IPO Debt | 30M |
| 8/2008 | Aposense | Venture Round | 7.3M |
| 9/2020 | Allena Pharmaceuticals | Post-IPO Debt | 25M |
| 6/2013 | Rewalk Robotics | Series D | 0 |
| 3/2019 | Prevail Therapeutics | Series B | 50M |
| 9/2020 | Silverback Therapeutics | Series C | 85M |
| 12/2019 | Metabomed | Series B | 0 |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 1/2021 | Abcuro | Series A | 42M |
| 12/2021 | ARMGO,Pharma,Inc. | Series B | 0 |
| 1/2016 | Adicet Bio | Series A | 51M |
| 12/2021 | Anaveon | Series B | 0 |
| 9/2019 | Adicet Bio | Series B | 0 |
| 4/2016 | Metabomed | Series A | 18M |
| 1/2020 | Eyevensys | Series B | 30M |
| 3/2021 | StrideBio | Series B | 0 |
| 7/2020 | Vico Therapeutics | Series A | 31M |
| 1/2020 | PACT Pharma | Series C | 0 |
| 9/2020 | Neogene Therapeutics | Series A | 110M |
| 3/2022 | Precirix | Series B | 0 |
| 9/2020 | Fore Biotherapeutics | Series C | 57M |
| 4/2018 | V-Wave | Series C | 0 |
| 4/2019 | AgomAb Therapeutics | Series A | 23.6M |
| 3/2021 | AgomAb Therapeutics | Series B | 0 |
| 12/2021 | Emergence Therapeutics | Series A | 0 |
| 3/2020 | Silverback Therapeutics | Series B | 0 |
| 4/2021 | Theseus Pharmaceuticals | Series B | 0 |
| 6/2017 | Tisbury Pharmaceuticals | Series A | 32M |
| 4/2010 | ProtAb | Series A | 4M |
| 3/2011 | Stimatix GI | Venture Round | 1M |
| 9/2020 | V-Wave | Series C | 0 |
| 3/2021 | EyeYon | Series C | 25M |
| 3/2018 | Prevail Therapeutics | Series A | 75M |
| 6/2005 | CritiSense | Venture Round | 1M |
| 10/2018 | 89bio | Series A | 60M |
| 9/2012 | cCAM Biotherapeutics | Series A | - |
| 1/2016 | Arno Therapeutics | Post-IPO Equity | 0 |
| 9/2006 | Collplant | Venture Round | 1.5M |
| 2/2018 | ABAC Therapeutics | Series A | 0 |
| 1/2017 | ARTSaVIT | Series A | 6.3M |
| 8/2016 | Arno Therapeutics | Post-IPO Equity | 8M |
| 5/2019 | Pi Therapeutics | Series B | 19.7M |
| 7/2010 | Avraham Pharmaceuticals | Series A | 9M |
| 4/2015 | EyeYon | Venture Round | 3.6M |
| 1/2019 | Keros Therapeutics | Series B | 0 |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 11/2017 | ArQule | Post-IPO Equity | 9.5M |
| 7/2016 | Entera Bio | Venture Round | 7.5M |
| 2/2007 | Collplant | Venture Round | 2M |
| 5/2010 | Aposense | Venture Round | 3M |
| 10/2017 | VBI Vaccines | Post-IPO Equity | 71.9M |
| 12/2019 | Raziel Health | Series C | 0 |
| 3/2017 | EyeYon | Venture Round | 6.5M |
| 8/2020 | Saniona | Post-IPO Equity | 0 |
| 5/2013 | UroGen Pharma | Series A | 7M |
| 3/2021 | Step Pharma | Series B | 0 |
| 10/2017 | CathWorks | Series B | 0 |
| 8/2016 | Nutrinia | Series D | 30M |
| 7/2013 | HeadSense Medical | Venture Round | - |
| 6/2017 | Eloxx | Series C | 30M |
| 9/2021 | Amolyt Pharma | Series B | 0 |
| 11/2018 | Precirix | Series A | 41.9M |
| 10/2020 | Opiant Pharmaceuticals | Debt Financing | 50M |
| 7/2018 | Dynacure | Series A | 55.2M |
| 4/2020 | Dynacure | Series C | 54.2M |
| 4/2016 | TargEDys | Series A | 6.5M |
| 4/2017 | TargEDys | Series A | 3.7M |
| 5/2015 | Otic Pharma | Series C | - |
| 6/2006 | CritiSense | Venture Round | 0 |
| 4/2010 | Applied Immune Technologies | Venture Round | 4M |
| 4/2008 | Collplant | Venture Round | 8.3M |
| 4/2007 | Collplant | Venture Round | 4.5M |
| 10/2014 | Check-Cap | Debt Financing | 0 |
| 7/2013 | V-Wave | Equity | 2M |
| 9/2016 | Eyevensys | Series A | 10.1M |
| 4/2011 | MacroCure | Venture Round | 13M |
| 4/2016 | Sweetch | Series A | 3.5M |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 12/2014 | Nutrinia | Series C | 12M |
| 3/2020 | Keros Therapeutics | Series C | 0 |
| 7/2019 | Amolyt Pharma | Series A | 0 |
| 6/2020 | Mereo Biopharma | Post-IPO Equity | 0 |
| 4/2023 | ADCendo | Series A | 0 |
| 11/2017 | Step Pharma | Series A | 17M |
| 9/2020 | Novellus | Series C | 57M |
| 6/2017 | LogicBio Therapeutics | Series B | 45M |
| 10/2013 | Arno Therapeutics | Post-IPO Equity | 0 |
| 3/2022 | Precirix | Series B | 0 |
| 12/2021 | ARMGO,Pharma,Inc. | Series B | 0 |
| 12/2021 | Anaveon | Series B | 0 |
| 12/2021 | Emergence Therapeutics | Series A | 0 |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 9/2021 | Amolyt Pharma | Series B | 0 |
| 4/2021 | Theseus Pharmaceuticals | Series B | 0 |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 3/2021 | Step Pharma | Series B | 0 |
| 3/2021 | StrideBio | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
